Literature DB >> 12632200

[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.

J G Rajendran1, D C Wilson, E U Conrad, L M Peterson, J D Bruckner, J S Rasey, L K Chin, P D Hofstrand, J R Grierson, J F Eary, K A Krohn.   

Abstract

Hypoxia imparts resistance to radiotherapy and chemotherapy and also promotes a variety of changes in tumor biology through inducible promoters. The purpose of this study was to evaluate the use of positron emission tomography (PET) imaging with fluorine-18 fluoromisonidazole (FMISO) in soft tissue sarcomas (STS) as a measure of hypoxia and to compare the results with those obtained using [(18)F]fluorodeoxyglucose (FDG) and other known biologic correlates. FDG evaluates energy metabolism in tumors while FMISO uptake is proportional to tissue hypoxia. FMISO uptake was compared with FDG uptake. Vascular endothelial growth factor (VEGF) expression was also compared with FMISO uptake. Nineteen patients with STS underwent PET scanning with quantitative determination of FMISO and FDG uptake prior to therapy (neo-adjuvant chemotherapy or surgery alone). Ten patients receiving neo-adjuvant chemotherapy were also imaged after chemotherapy but prior to surgical resection. Standardized uptake value (SUV) was used to describe FDG uptake; regional tissue to blood ratio (>or=1.2 was considered significant) was used for FMISO uptake. Significant hypoxia was found in 76% of tumors imaged prior to therapy. No correlation was identified between pretherapy hypoxic volume (HV) and tumor grade ( r=0.15) or tumor volume ( r=0.03). The correlation of HV with VEGF expression was 0.39. Individual tumors showed marked heterogeneity in regional VEGF expression. The mean pixel-by-pixel correlation between FMISO and FDG uptake was 0.49 (range 0.09-0.79) pretreatment and 0.32 (range -0.46-0.72) after treatment. Most tumors showed evidence of reduced uptake of both FMISO and FDG following chemotherapy. FMISO PET demonstrates areas of significant and heterogeneous hypoxia in soft tissue sarcomas. The significant discrepancy between FDG and FMISO uptake seen in this study indicates that regional hypoxia and glucose metabolism do not always correlate. Similarly, we did not find any relationship between the hypoxic volume and the tumor volume or VEGF expression. Identification of hypoxia and development of a more complete biologic profile of STS will serve to guide more rational, individualized cancer treatment approaches.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12632200     DOI: 10.1007/s00259-002-1096-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  54 in total

1.  Correlation of high lactate levels in head and neck tumors with incidence of metastasis.

Authors:  S Walenta; A Salameh; H Lyng; J F Evensen; M Mitze; E K Rofstad; W Mueller-Klieser
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

2.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole.

Authors:  W J Koh; J S Rasey; M L Evans; J R Grierson; T K Lewellen; M M Graham; K A Krohn; T W Griffin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

3.  Intrapulmonary spread of established B16 melanoma lung metastases and lung colonies.

Authors:  C W Stackpole
Journal:  Invasion Metastasis       Date:  1990

4.  Performance characteristics of a whole-body PET scanner.

Authors:  T R DeGrado; T G Turkington; J J Williams; C W Stearns; J M Hoffman; R E Coleman
Journal:  J Nucl Med       Date:  1994-08       Impact factor: 10.057

5.  Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia.

Authors:  H Zhong; J W Simons
Journal:  Biochem Biophys Res Commun       Date:  1999-06-16       Impact factor: 3.575

6.  Tumor metabolic rates in sarcoma using FDG PET.

Authors:  J F Eary; D A Mankoff
Journal:  J Nucl Med       Date:  1998-02       Impact factor: 10.057

7.  The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases.

Authors:  J Costa; R A Wesley; E Glatstein; S A Rosenberg
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

8.  A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data.

Authors:  J J Casciari; M M Graham; J S Rasey
Journal:  Med Phys       Date:  1995-07       Impact factor: 4.071

9.  Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.

Authors:  A Giatromanolaki; M I Koukourakis; E Sivridis; H Turley; K Talks; F Pezzella; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

10.  Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas.

Authors:  K I Wijffels; J H Kaanders; P F Rijken; J Bussink; F J van den Hoogen; H A Marres; P C de Wilde; J A Raleigh; A J van der Kogel
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

View more
  80 in total

Review 1.  Radionuclide imaging of perfusion and hypoxia.

Authors:  George Laking; Pat Price
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

Review 2.  Imaging radiation response in tumor and normal tissue.

Authors:  Marjan Rafat; Rehan Ali; Edward E Graves
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-06-15

3.  Imaging Hypoxia with ¹⁸F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis.

Authors:  Mark Muzi; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2016-02-18       Impact factor: 10.057

4.  To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [18F]FMISO-PET in Patients with Non-small Cell Lung Cancer.

Authors:  Li Li; Yuchun Wei; Yong Huang; Qingxi Yu; Wenju Liu; Shuqiang Zhao; Jinsong Zheng; Hong Lu; Jinming Yu; Shuanghu Yuan
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

Review 5.  Positron emission tomography imaging of cancer biology: current status and future prospects.

Authors:  Kai Chen; Xiaoyuan Chen
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

6.  Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images.

Authors:  Stanley Gu; Gargi Chakraborty; Kyle Champley; Adam M Alessio; Jonathan Claridge; Russell Rockne; Mark Muzi; Kenneth A Krohn; Alexander M Spence; Ellsworth C Alvord; Alexander R A Anderson; Paul E Kinahan; Kristin R Swanson
Journal:  Math Med Biol       Date:  2011-05-11       Impact factor: 1.854

Review 7.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 8.  Assessing tumor hypoxia by positron emission tomography with Cu-ATSM.

Authors:  J P Holland; J S Lewis; F Dehdashti
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-04       Impact factor: 2.346

9.  Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx.

Authors:  Matthew J Nyflot; Paul M Harari; Stephen Yip; Scott B Perlman; Robert Jeraj
Journal:  Radiother Oncol       Date:  2012-10-13       Impact factor: 6.280

10.  Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.

Authors:  Carmen S Dence; Datta E Ponde; Michael J Welch; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.